Clinical Research Directory
Browse clinical research sites, groups, and studies.
Risk-adapted Therapeutic Strategy in +1q NDMM
Sponsor: FengYan Jin
Summary
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.
Official title: Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2025-09-15
Completion Date
2029-07-04
Last Updated
2025-09-15
Healthy Volunteers
No
Conditions
Interventions
risk-scoring model
This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.
Locations (1)
The First Hospital of Jilin University
Changchun, Jilin, China